Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
27.45
+0.40 (1.48%)
At close: Apr 28, 2026, 4:00 PM EDT
27.89
+0.44 (1.60%)
After-hours: Apr 28, 2026, 4:18 PM EDT
Neurogene Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Neurogene stock have an average target of 63.57, with a low estimate of 24 and a high estimate of 180. The average target predicts an increase of 131.58% from the current stock price of 27.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurogene stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 3 | 3 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $200 → $180 | Strong Buy | Maintains | $200 → $180 | +555.74% | Apr 6, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $200 | Strong Buy | Initiates | $200 | +628.60% | Feb 27, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $50 | Buy | Initiates | $50 | +82.15% | Jan 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +155.01% | Jan 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $65 → $70 | Strong Buy | Maintains | $65 → $70 | +155.01% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.24
from -4.24
EPS Next Year
-5.90
from -5.24
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -4.37 | -5.18 | ||||
| Avg | -5.24 | -5.90 | ||||
| Low | -7.15 | -6.70 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.